Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9060MR)

This product GTTS-WQ9060MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9060MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14773MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ14115MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ10660MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ6469MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ1922MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ4693MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ2675MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ15922MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XOMA 052
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW